Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases

Kuan WANG; Yan ZHAN; Li JIANG; Jiashang HUANG; Yi XIANG; Quanhong SHI; Yanfeng XIE

doi:10.16016/j.1000-5404.202007251

您当前的位置：

首页 >

文章列表页 >

Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases

Clinical Medicine | 更新时间：2026-01-09

- Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases
- Journal of Third Military Medical University Vol. 42, Issue 24, Pages: 2426-2432(2020)
- 作者机构：
  
  400016 重庆，重庆医科大学附属第一医院神经外科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202007251
  CLC： R651.1;R742.5
- Received：31 July 2020，
  
  Revised：2020-10-07，
  
  Published：30 December 2020
- 稿件说明：
移动端阅览
Kuan WANG, Yan ZHAN, Li JIANG, et al. Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases[J]. Journal of Third Military Medical University, 2020, 42(24): 2426-2432.
DOI：

Kuan WANG, Yan ZHAN, Li JIANG, et al. Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases[J]. Journal of Third Military Medical University, 2020, 42(24): 2426-2432. DOI： 10.16016/j.1000-5404.202007251.

摘要

目的

评估丘脑底核(subthalamic nucleus，STN)脑深部电刺激术(deep brain stimulation，DBS)对伴有异动的帕金森病的治疗效果，并探讨STN-DBS治疗异动症状(levodopa-induced dyskinesia，LID)的可行性及其可能机制。

方法

对2016年3月至2019年12月于本中心行STN-DBS治疗的帕金森病患者进行回顾性分析。术前及术后6个月随访均使用统一帕金森病评定量表(UPDRS)Ⅲ部分、Ⅳ部分和异动评分(UPDRS Ⅳ部分第32~34项)以及左旋多巴等效剂量(levodopa equivalent daily dose，LEDD)评估疗效。

结果

STN-DBS术后6个月，最终所纳入的12例患者异动症状均明显改善，UPDRS Ⅳ评分和异动评分术后改善率分别为(45.91±13.01)%和(61.96±22.03)%。术后6个月，有2例患者左旋多巴等效剂量维持术前剂量，其余10例患者均减少了药物剂量，最高者减药率达72.00%，平均43.58%。同时，所有患者运动症状也得到显著改善，UPDRS Ⅲ评分关期改善率为(68.14±9.51)%。

结论

STN-DBS能明显改善帕金森患者的异动症状，其不仅能通过减药控制异动症，还能对异动症有直接抑制作用。

Abstract

Objective

To evaluate the clinical effectiveness of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD)

and to explore the feasibility and the possible underlying mechanism of the treatment.

Methods

A retrospective review was conducted on all the PD patients who underwent STN-DBS in our department from March 2016 to December 2019. Unified Parkinson's Disease Rating Scale (UPDRS) part Ⅲ and part Ⅳ

dyskinesia subscore (items 32 to 34 of UPDRS part Ⅳ) and the levodopa equivalent daily dose (LEDD)

which were used to evaluate the improvement of the symptoms before and in 6 months after operation.

Results

In 6 months after STN-DBS

the LID symptoms of the 12 patients finally enrolled were significantly improved

with the improvement rates of UPDRS Ⅳ score and dyskinesia subscore of (45.91±13.01)% and (61.96±22.03)%

respectively. Among them

the LEDD was maintained in 2 patients

and reduced in the other 10 patients

with the averagely reduced rate of 43.58%

and the highest rate of 72.00%. Meanwhile

the motor symptoms of all patients were also significantly improved

and the improvement rate of UPDRS Ⅲ score was (68.14±9.51)%.

Conclusion

STN-DBS significantly improves dyskinesia symptom of PD patients. Its anti-dyskinesia effect may be not only related to reduction of drug dose

but also to direct inhibition of LID.

关键词

Keywords

references

RADHAKRISHNAN D M, GOYAL V. Parkinson's disease: A review[J]. Neurol India, 2018, 66(Supplement): S26-S35. DOI: 10.4103/0028-3886.226451.

KIM J H, CHANG W S, JUNG H H, et al . Effect of subthalamic deep brain stimulation on levodopa-induced dyskinesia in Parkinson's disease[J ] . Yonsei Med J, 2015, 56(5): 1316-1321. DOI: 10.3349/ymj.2015.56.5.1316.

RIECK M, SCHUMACHER-SCHUHA F, CALLEGARI-JACQUES S M, et al . Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?[J ] . Pharmacogenomics, 2015, 16(6): 573-582. DOI: 10.2217/pgs.15.23.

ESPAY A J, MORGANTE F, MEROLA A, et al . Levodopa-induced dyskinesia in Parkinson disea se: Current and evolving concepts[J ] . Ann Neurol, 2018, 84(6): 797-811. DOI: 10.1002/ana.25364.

TRAN T N, VO T N N, FREI K, et al . Levodopa-induced dyskinesia: clinical features, incidence, and risk factors[J ] . J Neural Transm (Vienna), 2018, 125(8): 1109-1117. DOI: 10.1007/s00702-018-1900-6.

KUMAR N, VAN GERPEN J A, BOWER J H, et al . Levodopa-dyskinesia incidence by age of Parkinson's disease onset[J ] . Mov Disord, 2005, 20(3): 342-344. DOI: 10.1002/mds.20360.

EVANS J R, MASON S L, WILLIAMS-GRAY C H, et al . The natural history of treated Parkinson's disease in an incident, community based cohort[J ] . J Neurol Neurosurg Psychiatry, 2011, 82(10): 1112-1118. DOI: 10.1136/jnnp.2011.240366.

TURCANO P, MIELKE MM, BOWER J H, et al . Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study[J ] . Neurology, 2018, 91(24): e2238-e2243. DOI: 10.1212/wnl.0000000000006643.

HUOT P, JOHNSTON T H, KOPRICH J B, et al . The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease[J ] . Pharmacol Rev, 2013, 65(1): 171-222. DOI: 10.1124/ pr.111.005678.

GROUP P M C. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmaticrandomised trial[J]. Lancet, 2014, 384(9949): 1196-1205. DOI: 10.1016/s0140-6736(14)60683-8.

FERREIRA J J, KATZENSCHLAGER R, BLOEM B R, et al . Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease[J ] . Eur J Neurol, 2013, 20(1): 5-15. DOI: 10.1111/j.1468-1331.2012.03866.x.

WOLF E, SEPPI K, KATZENSCHLAGER R, et al . Long-term antidyskinetic efficacy of amantadine in Parkinson's disease[J ] . Mov Disord, 2010, 25(10): 1357-1363. DOI: 10.1002/mds.23034.

HINDLE J V. The practical management of cognitive impairment and psychosis in the older Parkinson's diseasepatient[J]. J Neural Transm, 2013, 120(4): 649-653. DOI: 10.1007/s00702-013-0994-0.

FOLLETT K A, WEAVER F M, STERN M, et al . Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease[J ] . N Engl J Med, 2010, 362(22): 2077-2091. DOI: 10.10 56/nejmoa0907083.

MUNHOZ R P, CERASA A, OKUN M S. Surgical treatment of dyskinesia in Parkinson's disease[J]. Front Neurol, 2014, 5: 65. DOI: 10.3389/fneur.2014.00065.

LIU Y, LI F, LUO H, et al . Improvement of deep brain stimulation in dyskinesia in Parkinson's disease: a meta-analysis[J ] . Front Neurol, 2019, 10: 151. DOI: 10.3389/fneur.2019.00151.

ODEKERKEN V J, VAN LAAR T, STAAL M J, et al .Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial[J ] . Lancet Neurol, 2013, 12(1): 37-44. DOI: 10.1016/s1474-4422(12)70264-8.

FAN S Y, WANG K L, HU W, et al .Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia[J ] . Ann Clin TranslNeurol, 2020, 7(1): 59-68. DOI: 10.1002/acn3.50961.

OSTERGAARD K, SUNDE N, DUPONT E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations[J]. Mov Disord, 2002, 17(4): 693-700. DOI: 10.1002/mds.10188.

NISHIKAWA Y, KOBAYASHI K, OSHIMA H, et al . Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease: case report[J ] . Neurol Medico Chir, 2010, 50(3): 257-259. DOI: 10.2176/nmc.50.257.

GURIDI J, OBESO J A, RODRIGUEZ-OROZ M C, et al . L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease[J ] . Neurosurgery, 2008, 62(2): 311-323. DOI: 10.1227/01.neu.0000315998.58022.55.

KRACK P, POLLAK P, LIMOUSIN P, et al .From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity[J ] . Brain, 1999, 122 (Pt 6): 1133-1146. DOI: 10.1093/brain/122.6.1133.

RODRIGUEZ-OROZ M C. Efficacy of deep brain stimulation of thesubthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation[J]. J Neurol Neurosurg Psychiatry, 2004, 75(10): 1382-1385. DOI: 10.1136/jnnp.2003.031294.

BRODSKY M A, HOGARTH P, NUTT J G. OFF-off rebound dyskinesia insubthalamic nucleus deep brain stimulation of Parkinson's disease[J]. Mov Disord, 2006, 21(9): 1487-1490. DOI: 10.1002/mds.20964.

TOMASINO B, MARIN D, ELEOPRA R, et al . To move or not to move: subthalamic deep brain stimulation effects on implicit motor simulation[J ] . Brain Res, 2014, 1574: 14-25. DOI: 10.1016/j.brainres.2014.06.009.

JIANG Y G, TAN Z G, ZHOU Q, et al . Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials[J ] . Clin Interv Aging, 2016: 777. DOI: 10.2147/cia.s105505.

WAGLE SHUKLA A, OKUN M S. Surgical treatment of Parkinson's disease: patients, targets, devices, andapproaches[J]. Neurotherapeutics, 2014, 11(1): 47-59. DOI: 10.1007/s13311-013-0235-0.

ZHENG Z, LI Y, LI J, et al . Stimulation-induced dyskinesia in the early stage after subthalamic deep brain stimulation[J ] . Stereotact Funct Neurosurg, 2010, 88(1): 29-34. DOI: 10.1159/000260077

向怡, 蒋理, 覃彬, 等.帕金森病患者丘脑底核脑深部电刺激术中同期植入双侧电极精度及治疗效果的研究[J].第三军医大学学报, 2020, 42(05): 517-522. DOI: 10.16016/j.1000.5404.201910055.

XIANG Y, JIANG L, QIN B, et al .Precision of bilateral electrode implantation and treatment outcome in Parkinson's disease after subthalamic nucleus deep brain stimulation[J ] .J Third Mil Med Univ, 2020, 42(05): 517-522. DOI: 10.16016/j.1000.5404.201910055.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Precision of bilateral electrode implantation and treatment outcome in Parkinson's disease after subthalamic nucleus deep brain stimulation

SOCS3 ameliorates Parkinson’s disease neuropathology by suppressing NF-κB signaling-mediated microglial inflammation

Differences in motor function and psychological factors across phenotypic patterns of freezing of gait in Parkinson’s disease

Correlation between change in choroid plexus volume and cognitive function in patients with Parkinson’s disease

Influencing factors for Pisa syndrome in patients with Parkinson’s disease

Related Author

Yi XIANG

Li JIANG

Bin QIN

Kuan WANG

Yisi LIAO

Quanhong SHI

Yanfeng XIE

LIU Yuqi

Related Institution

Graduate School， Guizhou University of Traditional Chinese Medicine

Department of Critical Care Medicine， Qingzhen First People’s Hospital

Graduate School， Zunyi Medical University

Department of General Medicine， Guizhou Provincial People’s Hospital

Department of Medical Psychology， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰